WHO initiative builds a coalition for system reforms, COVID-19 recovery in Europe


Organisation is kicking off a flagship initiative as it views mental health as a key public health concern in the WHO European region, where more than 110 million people are living with some type of mental health issue.

The World Health Organisation (WHO) announced a new flagship initiative, “a mental health coalition to support system reforms and COVID-19 recovery” in Europe.

This was undertaken because of the organisation’s recognition that “mental health is a key public health concern in the WHO European Region – more than 110 million people are living with some kind of mental health condition, accounting for over 10% of the population.”

“The mental health flagship will bring together a broad coalition of mental health leaders, champions, service users and other partners to improve mental health policies and practices across the region,” the WHO said in a statement.

Considering the COVID-19 virus, focusing on mental health now is especially important given that the measures to prevent the virus from spreading, such as social distancing and quarantining, in addition to the dangerous working conditions for health care workers, are having a psychological impact on the population and exacerbate pre-existing anxiety.

The WHO explained that the Mental Health Initiative will challenge “stigma and discrimination by improving mental health awareness and literacy among not only the public but also service providers and decision makers.”

In addition, it will enhance access to “person-centered, rights-based mental health care in communities. This will expedite progress towards universal health coverage for people with mental health conditions and make the case for a parity of esteem between mental and physical health.”

The Mental Health initiative is one of 4 launched by the WHO. The other 3 priorities for WHO/Europe over the next 5 years are digital health and innovation, behavioural and cultural insights, and immunization.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.